RegeneRx Issues Letter To Stockholders
On April 11, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) issued a Letter to Stockholders outlining its operational strategy and development focus. The company specializes in novel therapeutic peptides, particularly Thymosin beta 4 (Tβ4), targeting tissue protection, repair, and regeneration. RegeneRx is advancing three drug candidates in clinical trials for various medical conditions and holds four strategic licensing agreements across the U.S., China, and several Asian countries, as well as the EU. The letter includes forward-looking statements regarding financial needs, clinical trials, and partnerships, highlighting inherent risks and uncertainties, particularly concerning capital requirements and the success of ongoing clinical trials.
- Three drug candidates currently in clinical development.
- Four active strategic licensing agreements in multiple regions.
- Uncertainties regarding the ability to raise capital for operations.
- No guarantee of success in ongoing clinical trials.
About
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, acute inflammatory and dermal indications, four active strategic licensing agreements in the
Forward Looking Statements
Any statements in this press release and Letter to Stockholders that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this stockholder letter include, but are not limited to, statements regarding our current or future cash position, capital requirements, ability to continue operations, strategic and research partnerships, the development and timing of clinical trials for our drug candidates, the use of our drug candidates to treat various conditions, our operating strategies, intellectual property, and our financial needs. These, and any other forward-looking statements, are expectations and estimates based upon information obtained from our joint venture partner and/or calculated by the Company at this time and are subject to change. Moreover, there is no guarantee any of our clinical trials will be successful or confirm previous clinical results. There also is no assurance that we can successfully raise the capital required to continue even limited business operations now or in the future. Please view these and other risks described in the Company's filings with the
View original content:https://www.prnewswire.com/news-releases/regenerx-issues-letter-to-stockholders-301794921.html
SOURCE
FAQ
What did RegeneRx announce on April 11, 2023?
What are the main drug candidates developed by RegeneRx?
What risks are associated with RegeneRx's forward-looking statements?
How many licensing agreements does RegeneRx currently have?